User: I want to know more about the molecule with SMILES COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(=O)O.
Assistant: Sure, what is your question?
User: Please describe this drug.
Assistant: The answer is Pegaptanib is a 28-mer RNA aptamer covalently linked to two branched 20-kD polyethylene glycol (PEG) chains, with anti-angiogenic activity. Pegaptanib binds and blocks the activity of the extracellular vascular endothelial growth factor, specifically the 165-amino acid isoform (VEGF165). This prevents VEGF165 from binding to VEGF receptors, thereby blocking angiogenesis as well as preventing VEGF165-induced increases in vessel permeability. VEGF165 is preferentially involved in pathological ocular neovascularisation.
User: I want to know more about the {#molecule|chemical|compound!} with {SMILES__description} {SMILES#}.
Assistant: {#Sure, what is your question?|How can I help?|That sounds interesting, how can I help?|Interesting, how can I help?!}
User: {quest#}
Assistant: {#The answer is |!}{answ#}
COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(=O)O
COCCOC(=O)NCCCC[C@@H](C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC
7-[[(2S)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinicacid
Please describe this drug.
Pegaptanib is a 28-mer RNA aptamer covalently linked to two branched 20-kD polyethylene glycol (PEG) chains, with anti-angiogenic activity. Pegaptanib binds and blocks the activity of the extracellular vascular endothelial growth factor, specifically the 165-amino acid isoform (VEGF165). This prevents VEGF165 from binding to VEGF receptors, thereby blocking angiogenesis as well as preventing VEGF165-induced increases in vessel permeability. VEGF165 is preferentially involved in pathological ocular neovascularisation.